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Abstract
Background: Oral squamous cell carcinoma (OSCC) is associated with substantial mortality and morbidity but,
OSCC can be difficult to detect at its earliest stage due to its molecular complexity and clinical behavior. Therefore,
identification of key gene signatures at an early stage will be highly helpful.
Methods: The aim of this study was to identify key genes associated with progression of OSCC stages. Gene
expression profiles were classified into cancer stage-related modules, i.e., groups of genes that are significantly
related to a clinical stage. For prioritizing the candidate genes, analysis was further restricted to genes with high
connectivity and a significant association with a stage. To assess predictive power of these genes, a classification
model was also developed and tested by 5-fold cross validation and on an independent dataset.
Results: The identified genes were enriched for significant processes and functional pathways, and various genes
were found to be directly implicated in OSCC. Forward and stepwise, multivariate logistic regression analyses
identified 13 key genes whose expression discriminated early- and late-stage OSCC with predictive accuracy (area
under curve; AUC) of ~0.81 in a 5-fold cross-validation strategy.
Conclusions: The proposed network-driven integrative analytical approach can identify multiple genes
significantly
related to an OSCC stage; the classification model that is developed with these genes may help to distinguish
cancer stages. The proposed genes and model hold promise for monitoring of OSCC stage progression, and our
findings may facilitate cancer detection at an earlier stage, resulting in improved treatment outcomes.
Keywords: Coexpression network analysis, Gene module, Hub gene, Microarray, Oral squamous cell carcinoma,
Logistic regression modeling
Background
Oral cancer is a common cancer worldwide with squa-
mous cell carcinoma being the most prevalent subtype,
which accounts for 96 % of oral-cavity cancers [1]. There
are ~260,000 new cases of oral squamous cell carcinoma
(OSCC) and 124,000 deaths worldwide annually [2].
Despite considerable advances in treatments, the overall
five-year survival rate of patients at the advanced stage is
only 30 %, but is greater than 90 % among patients with
early-stage OSCC [3]. Unfortunately, only 35 % of cases
of oral cancer are detected at the earliest stage (without
producing symptoms) [4]because of its molecular com-
plexity and clinical behavior. Therefore, there is an ur-
gent need for identifying molecular predictors that may
enable cancer detection at early stages.
Remarkable advances in technologies for assaying gene
expression and the availability of high-throughput data
have opened up new avenues of cancer research that
may allow researchers to generate hypotheses regarding
improved disease classification. Global gene expression
profiles in OSCC have been studied using traditional
approaches which have helped to identify some candidate
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gene biomarkers on the basis of comparison between can-
cerous and non-cancerous cases [5–7]. In addition, several
computational methods have been developed to identify
biomarkers for oral cancer prognosis and diagnosis
[8–10]. Comparative analysis of expression profiles be-
tween early and late stages has uncovered genes with
stage-dependent alterations in expression of various can-
cers [11, 12]; however, to our knowledge, not much efforts
has been devoted to analysis of OSCC stage progression
in relation to aggressiveness of the cancer.
Genes and proteins function cooperatively and thus
regulate common biological processes by co-regulating
each other [13]; however, genes identified via the classical
approaches are usually not functionally related and there-
fore may not reveal key biological processes. Because of
these limitations, the traditional approaches are not very
useful for identification of specific genes that contribute to
or are affected by complex diseases. Fortunately, rapid ad-
vances in network biology have effectively provided valu-
able frameworks for analysis of multidimensional biological
data and have important applications to clinical practice.
Instead of analyzing tens of thousands of gene com-
parisons, the network-based analysis offers a meaning-
ful data reduction scheme that limits the analysis to
only hundreds [14–16] or even tens [17–20] of rele-
vant genes. Altered gene coexpression networks have
been proven to be the major cause of dysregulated
expression during cancer progression [21, 22]. Dis-
eases can therefore be studied as networks by system-
atically exploring topological associations between
contributing genes. Gene coexpression networks have
been utilized even to identify key tumorigenic genes
with the aim to find biomarkers or to gain insights
into probable disease mechanisms. Nevertheless, most
of these studies remain limited to physically interact-
ing genes and do not take into account their associa-
tions with the disease phenotype. On the other hand,
disruption in connections within disease modules give
rise to particular disease phenotypes [23]. Thus, now
it seems to be more important to consider the pheno-
typic association in order to characterize the mecha-
nisms of disease progression [24].
A complex alteration of global gene expression profiles
among genes is a determinant of progression of cancer
stages and grades [25–27].Because genes that are highly
connected within a gene set are thought to drive other
genes [28], it was hypothesized that examining the altered
gene expression profiles of key genes might help to discrim-
inate between early and late stage cancers. Although cancer
stage is an effective prognostic factor, to the best of our
knowledge, systematic studies characterizing gene expres-
sion data in relation to OSCC stage progression are scarce.
In the present study, we identified key genes associated
with OSCC stage and developed a classification model
to discriminate the two most common OSCC groups:
early stages (I, II) versus late stages (III, IV). For this pur-
pose, first, a set of highly correlating genes was obtained
from a gene coexpression network. For prioritizing the
candidate genes, the analysis were then restricted to genes
with high connectivity and a significant association with
cancer stage. To advance the understanding of these
relations, using expression profiles of the putative gene
candidates, we then develop a classification model to dis-
criminate cancer stages; this model helped to classify
OSCC efficiently. The methodology presented herein
seems to be the first implementation of key hub genes (de-
pending on topological and phenotypic importance) to
identify an OSCC stage and may predict clinical aggres-
siveness of this cancer.
Methods
To identify the key genes whose expression may discrim-
inate between early- and late-stage OSCC samples, we
adopted the following major steps: (1) merging of multiple
microarray datasets to identify differentially expressed
genes (DEGs) in tumor samples compared to normal
(healthy) controls, (2) analysis of the gene coexpression
network to identify stage associated modules and their key
hub genes, and (3) development of a hub gene-based clas-
sifier model to distinguish OSCC stages. Schematic repre-
sentation of the overall strategy is shown in Fig. 1.
Acquisition and proecessing of gene expression data
Gene expression profiles of OSCC were obtained from the
National Center for Biotechnology Information (NCBI)
Gene Expression Omnibus (GEO) database [29] via quer-
ies with the search terms “oral squamous cell carcinoma”
and “head and neck squamous cell carcinoma” (August,
2014) to specifically retrieve most widely used Affymetrix
HGU-133a and HGU-133plus2 array datasets (Table 1).
Studies that had well-defined phenotypic description of
cancer stage were preferred. Other criteria included: (i)
samples comprising only human tissue (not derived from
cell lines) and without any history of specific treatment,
(ii) studies comprising both case samples and healthy con-
trol samples (to identify disease-specific signals), and (iii)
studies that were conducted on similar platforms (we
wanted to obtain a high proportion of overlapping genes).
Individual datasets were imported into the R 3.0.2 statis-
tical environment (www.r-project.org) by means of the
GEOquery tool of the Bioconductor software package
(version 2.22.0) [30] and were processed using affy pack-
age. At initial levels of quality control (QC), all sam-
ples were pre-processed together using the standard
affyQCReport and affyPLM quality assessment soft-
ware packages. The Harshlight package [31] was utilized
to remove the effects of spatial blemishes. As a general
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principle, chips with extensive defects were eliminated
from the datasets. Background correction, quantile
normalization and summarization were performed by
means of the frozen robust multi-array average (fRMA)
algorithm [32] using the frma package. Probesets were
mapped to the human genome in the annotate and
hgu133plus2.db software packages.
Merging the datasets and identification of DEGs
The COMBAT (empirical Bayes [33]) batch correction
and cross-platform normalization method which is
implemented in the inSilicoMerging package [34], was
used to merge all normalized microarray datasets into one
global merged dataset. The merging was performed by
means of common identifiers to obtain common space
across all platforms, with 22,277 genes in total. To assess
the removal of the microarray bias effect across the
datasets, another merged dataset without batch effect
removal was also compiled. The datasets were pro-
jected onto the planes defined by the first two princi-
pal components. In addition, hierarchical clustering
was performed using gplots software package. Ward’s
method with the Euclidean distance metric was used
for the clustering.In the biosvd [35] software package,
the merged dataset was subjected to filtering out of
eigengenes and eigenarrays—that were assumed to
represent noise—by measuring steady-state gene ex-
pression and steady-scale variance. We performed
nonspecific filtering using the library genefilter, to re-
move QC probe sets and genes with low overall vari-
ability as a standard procedure. Linear modeling and
tests for differential expression, adjusted for multiple
testing, were performed in the Linear Models for
Microarray Analysis (LIMMA) [36] software package.
Table 1 A list of Affymetrix datasets used in the study
Dataset identifier Initial number of samples
(Tumor + Normal)
Samples (Tumor + Normal) left after
initial preprocessing
Affymetrix platform Reference
GSE31056 47 (23 + 24) 47 (23 + 24) HGU-133plus2 [137]
GSE9844 38 (26 + 12) 38 (26 + 12) HGU-133plus2 [5]
GSE30784 212 (167 + 45) 210 (165 + 45) HGU-133plus2 [138]
GSE3524 20 (16 + 4) 20 (16 + 4) HGU-133a [139]
GSE42743 103 (74 + 29) 100 (73 + 27) HGU-133plus2 [96]
GSE2280 27 (22 + 5) 27 (22 + 5) HGU-133a [140]
GSE6791 44 (30 + 14) 44 (30 + 14) HGU-133plus2 [141]
Fig. 1 The steps involved in systems level analysis of data on oral squamous cell carcinoma (OSCC). a Microarray data collection and
preprocessing of experiments to identify differentially expressed genes (DEGs). b Construction of the OSCC network and identification of an OSCC
stage-associated module and of cancer hub genes. c Development and testing of a key hub gene-based classifier model by
5-fold cross-validation
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Genes with a twofold higher or lower differential ex-
pression, and a false discovery rate (FDR) < 0.05 were
selected as genes differentially expressed in tumor
samples compared to normal controls.
Construction and validation of a coexpression network
The coexpression network analysis was performed in the
Weighted Gene Correlation Network Analysis (WGCNA)
[37] software to identify modules of highly correlating
genes. After initial data preprocessing for network analysis
and removal of outliers, 347 tumor samples, which were
further categorized into early- and late-stage samples,
were used to construct a signed network, i.e., a network
that preserves the sign of correlations among expression
profiles. WGCNA defined the network into color-coded
modules assigned according to the size (number of genes)
with each module containing a set of unique genes. To as-
sess the robustness of this definition of a coexpression
module and to test whether the resulting modules were of
high quality (rather than generated by chance), we exam-
ined their reproducibility by a resampling procedure [38].
Two methods to generate Z-summary scores were used.
First, module statistics of the merged dataset (reference
dataset) was compared to the randomly generated modules
in a test dataset, which comprised 100 random samples
from the reference dataset. Second, we also replicated
module preservation analysis over individual GEO
datasets by assuming that they were test datasets.
Further, to incorporate the OSCC phenotype status
into the coexpression network and identify stage-
associated modules, we tried to find correlation of
each module with disease phenotype. Modules that
significantly correlated with stage phenotype were la-
beled “candidate modules”. In our analysis, only one
module (pink) was found to correlate with a stage
and therefore was analyzed further. The gene coex-
pression network for the candidate module was then
visualized by importing network data into Cytoscape,
version 3.0.1 [39]. To adjudge the scale-free nature of
degree distributions of network, discrete power-law
hypothesis was tested using poweRlaw software pack-
age [40]. Detailed information on the construction of
coexpression network is provided in Supporting Infor-
mation (Additional file 1: Supplementary Methods).
Assessment of topological robustness of significant
module(s)
This procedure was conducted by performing analyses of
simultaneous node deletions [41] and by observing
changes in the size of the largest component, σ(ρ), when
the fraction ρ of vertices (nodes) was removed in a se-
quential manner. Importance of nodes was determined by
first calculating critical topological centrality measures
[42], including degree (k), betweenness centrality (BC),
closeness centrality (CC), and eigenvector centrality (EC),
for all nodes and then removing a certain fraction (ρ) of
the nodes. Nodes were removed in the decreasing central-
ity order, consecutively followed by removal of nodes uni-
formly at random and by examination of changes in the
size of the largest component. For the sake of simplicity,
the network was assumed to be unweighted. The vulner-
ability of the network to a given scheme of vertex removal
was quantified by computing the V-index, a value comple-




Identification of cancer hub genes and enrichment
analysis
An ensemble of gene significance (GSiGS) and intramod-
ular connectivity (Ki) were considered to identify hub
genes within cancer stage-associated module. Intramod-
ular hub genes were selected based on stronger correl-
ation with an OSCC stage (GSi>0.2) and higher
connectivity (Ki > 0.3). GSi describes strength of a correl-
ation between a gene and a phenotypic trait. The higher
the GSiGS, the stronger the gene’s absolute correlation
with the trait of interest is. Conversely, intramodular
connectivity was computed from the sum of its connec-
tion strengths with all other genes in the same module;
this parameter is also called “scaled connectivity” (Ki). Ki
is measured as follows:
Ki ¼ kikmax
where ki is the connectivity of a gene, and kmax is the
maximal connectivity of the gene.
For enrichment analysis, Signaling Pathway Impact
Analysis (SPIA) was performed on the hub genes using
an ensemble of SPIA [43] and GRAPH Interaction from
pathway Topological Environment (GRAPHITE) [44]
software packages that predicted possible functional
pathways dysregulated in OSCC. Next, gene ontology
(GO) enrichment analysis was performed by the stand-
ard hypergeometric test from the GOstats [45] software
package and Gene Ontology Consortium database [46],
to identify categories of statistically over-represented
biological processes (BP). To facilitate the interpretation
and visualization of significantly enriched GO categories
(p < 0.01), we used Reduce and Visualize Gene Ontology
(REVIGO) (http://revigo.irb.hr/) [47].
Construction of the stage classification model
The multivariate R package glmnet [48] was used to
perform elastic-net feature selection by linear regres-
sion modeling. During this procedure, Classification And
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REgression Training (CARET) [49] package was set up to
fine-tune both regularized parameters: α, the elastic net
mixing parameter, and λ, the tuning parameter. After
1000 bootstraps, a frequency (f ) ranked gene list was ob-
tained on the basis of how often a gene was included in
each bootstrap. Final hub gene signatures of the pheno-
type consisted of genes that were present in a >90th per-
centile cut off of the fourth quartile (750) of all bootstrap
samples. All relevant features with non-zero coefficients
were retained and assumed to be “key hub genes”. To as-
sess classification power of the identified genes, a model
was built in the glmnet software package. The model con-
struction was based on 70 % of the training data, while
model evaluation was performed on the remaining 30 %
of testing data, with samples categorically classified into
an early and late stage. Training was carried out by 5-fold
cross-validation (each dataset was bootstrapped 5 times).
The resulting model was then evaluated on the corre-
sponding testing dataset.
Predictive performance was quantified by means of
area under the receiver-operating characteristic (ROC)
curve (AUC) by plotting the ROC curve in the pROC
software package [50]. Furthermore, the classification
model that was developed from the merged dataset was
also evaluated on an independent dataset, and prediction
power was further assessed. All computations were car-
ried out on a 12-core HPZ600 workstation running the
Ubuntu 12.04 operating system.
Results
Our analysis consisted of several steps: a flow chart of
the method is provided in Fig. 1. The results of our ana-
lysis are summarized in the following major steps: (1)
data acquisition and merging of multiple microarray
datasets to identify DEGs in tumor samples, (2) analysis
of the gene coexpression network to identify cancer
stage-associated modules, and (3) identification of can-
cer hub genes and development of a key hub gene-based
classifier model to distinguish OSCC stages. Details of
each step are summarized below.
Data pre-processing
A total of six relevant experiments were obtained and
five of them (five experimental designs) were explicitly
dedicated to OSCC, whereas one was available for head
and neck squamous cell carcinoma (HNSCC). A small
sample size may result in unstable gene lists and poor
prediction accuracy in studies on the differential gene
expression [51]. Because the initial total number of sam-
ples obtained from six studies was small (191 cancer pa-
tients and 88 healthy (normal) subjects), an additional
dataset (GSE30784) that lacked phenotypic details but
contained a large number of OSCC samples (167 cancer
patients and 45 healthy (normal) controls), was also
included to ensure a sufficient sample size in this study.
In the experiment involving HNSCC tissues, special care
was taken to exclude non-OSCC samples. Hierarchical
clustering analysis indicated that normal and tumor
samples were grouped together with few outliers; how-
ever, separation between OSCC and normal groups was
clearly observed. These observations implied that gene
expression profiles of tumor samples were likely to be
disordered in comparison with the healthy controls.
Summary statistics of the fitted robust linear model was
used to identify problematic chips: datasets GSE9844,
GSE30784, GSE3524, GSE42743, and GSE2280 con-
tained hybridization artefacts. Small localized artefacts
may not be a cause for concern but some chips con-
tained extensive defects: blemishes that affected most of
the chip and therefore maximal number of probes.
These chips were eliminated from further analysis as a
standard procedure (Table 1).
Because we analyzed samples from multiple studies
and thus from multiple arrays, the resulting gene
expression data could be affected by batch effects: a
non-biological experimental variation. The fRMA algo-
rithm utilizes a platform-dependent background model
to normalize the expression values [34]: therefore, the
samples are clustered by platform and not by study. It
was observed that normalisation introduced major devi-
ating intensity levels into distributions with similar char-
acteristics (Additional file 2: Figures S1 and S2).
Furthermore, existence of any potentially defective ar-
rays was also ruled out. The overall number of tumor
(355) and non-tumor (131) samples was large enough to
overcome the sample size restriction for differential-
expression studies.
Data merging and removal of the batch effect
Gene expression data that were generated by different
processing facilities could not be combined directly for
downstream analysis, even after processing with a simi-
lar normalization method. Many methods for batch ef-
fect removal have been developed [52], but COMBAT is
believed to outperform other commonly used batch-
adjustment methods [53]. In the present study, a
COMBAT-merged dataset consisted of 22,277 genes in
total, all of which mapped to distinct identifiers. The
dataset was projected onto planes defined by the first
two principal components via inspection of multi di-
mensional scaling (MDS) plots (Fig. 2). Principal compo-
nents partition data into orthogonal linear components
reflecting different contributions to variability in the
data, with the first component explaining the largest
contribution and the second component the second lar-
gest, and so on. To see impact of the batch effect, we
also compiled another merged dataset without removal
of the batch effect. Figure 2a shows that without
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additional transformation, all samples were clustered by
experiment and by platform inside the MDS space and
not by the biological variable of interest (normal versus
tumor). This result indicated that the biggest source of
variation was technical rather than biological. Inside
each study, however, there was a clear separation be-
tween normal (healthy) and tumor samples. As expected,
after implementation of intra-platform batch adjustment,
the samples were intermingled on the basis of the
biological variable (Fig. 2b); this situation means removal
of dataset-specific biases and elimination of batch effects
to a greater extent (though not complete elimination)
and may facilitate clinically important analysis of the
underlying biology.
Hierarchical clustering of the dataset comprising
1000 random genes was performed by Ward’s method
with the Euclidean distance metric. The clustering ana-
lysis revealed that the samples were grouped and repre-
sented by a data source (Additional file 2: Figure S3-A);
however, when they were simply combined, influence of
the data source on the study-based grouping was signifi-
cantly reduced after application of COMBAT (Additional
file 2: Figure S3 B). Relative log expression (RLE) boxplots
are proposed for validation of methods for batch effect re-
moval [54] and were also used to illustrate a global bias
between merged datasets. The RLE plot highlighted the
existence of seven visible batches in simply combined
datasets (Additional file 2: Figure S4 A), however COM-
BAT implementation improved the appearance of plot
(Additional file 2: Figure S4 B). Additionally, compared
to simply combined dataset (Additional file 2: Figure
S4 A), the mean of the RLE plot for the COMBAT-
processed dataset (Additional file 2: Figure S4 B) was
distributed around zero and had almost similar spread
for all samples; this situation was indicative of effect-
ive removal of the batch effect. These analyses clearly
showed that cross-platform comparison outperformed
the simple combining; therefore, the merged dataset
was eventually used for further downstream analysis.
Identification of DEGs
Filtering out of eigengenes and eigenarrays that are as-
sumed to represent noise enables meaningful comparison
of gene expression across different arrays in different ex-
periments [55]. Low entropy (0.02) in combination with
steady-state expression (~98 %) that were detected in the
first eigenfeature suggested that the underlying processes
were manifested by weak perturbations of the steady state
of expression, and this eigenfeature was therefore filtered
out. In contrast, no steady-scale variance was present in
the dataset.
Multiple eigenfeatures were required to explain most
of the variance; this result was indicative of the presence
of various interesting signals. The core of LIMMA is an
implementation of the empirical Bayes linear modeling
approach, and provides more stable inferences about dif-
ferential expression. Evaluation of the log ratio between
conditions and consideration of genes that differ by
more than an arbitrary cutoff represent reliable method
for identifying DEGs [56]. It is also common to select
those DEGs that satisfy both the p-value and fold change
criteria simultaneously because this combination typic-
ally results in more biologically meaningful sets of genes
[57–59]. In the present work, genes that simultaneously
possessed low probability values and a high log-fold
change were selected for analysis, where the t-statistic
computed probability values and fold change offered sta-
tistically stringent and possibly biologically meaningful
Fig. 2 A multidimensional scaling (MDS) plot of the merged gene expression data.a This panel shows that without removal of the batch effect,
all samples are clustered by experiment and by platform (not by the biological variable of interest) inside the MDS space. b With intra-platform
batch adjustment, the samples are intermingled on the basis of the biological variable. All samples are color coded by biological variables
(normal: red, cancer: green), with different symbols corresponding to different studies
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criteria, respectively. Of the 22,277 genes analyzed, a
total of 1652 genes were found to be differentially
expressed (1052 overexpressed and 600 underexpressed)
(Additional file 2: Figure S5) thereby presenting evidence
of variability between the case and control samples. To
test the discriminative ability of the selected DEGs, we
performed unsupervised hierarchical clustering of all
samples on the basis of similarity in gene expression. A
heatmap of the hierarchical clustering (Additional file 2:
Figure S6) showed that most of the tissue samples were
strictly clustered into their distinctly normal and cancer
groups. This finding indicated that the DEGs that we
identified could classify samples into their respective
groups depending on gene expression patterns and
therefore represented statistically significant genes.
Identification of gene coexpression modules
Because the transcripts that are involved in biological pro-
cesses may be upregulated or downregulated, a signed net-
work was created that allowed modules to contain
positively and negatively correlated genes in different
modules. WGCNA-weighted networks are highly robust
with respect to the choice of the β value and provide an
opportunity to construct networks with the scale-free cri-
terion. To ensure biological relevance of the OSCC net-
work, the β value of 18 was selected which resulted in a
network that was approximately scale-free, and yielded
the exceptionally high signed scale-free topology fit (R2) of
0.95. The node degree distribution for the network ap-
proximated a power-law distribution (Additional file 2:
Figure S7), an inherent characteristic of scale-free net-
works, indicating the presence of few exceptionally con-
nected genes in contrast to more frequent less connected
genes. Hierarchical clustering defined branches of the
cluster dendrogram in 13 color-coded modules (Fig. 3a)
ranging in size from 35 to 339 genes (average size of 127
genes). Each module that we obtained was assigned to an
arbitrary color according to size. Visual inspection of the
gene dendrogram revealed modular organization since the
genes whose expression highly correlated tended to cluster
together in the same branches. It is worth noting that the
grey module is always reserved for genes with dissimilar
expression patterns that do not cluster into any other
modules and therefore represent noise genes.
Robustness and preservation of modules
Analysis of statistics of network module preservation deter-
mines whether modules that were identified in one network
(reference) remain connected in another network (test) and
yields a Z-summary statistic: a composite measure of statis-
tics related to network density and connectivity. A module
shows no evidence of preservation among datasets if its Z-
summary statistic is smaller than two, whereas a statistics
between two and 10 is corresponds to moderately pre-
served (reproducible) module, and above 10 is to a strongly
preserved module [60]. While analyzing modules against
Fig. 3 Module assignments for the expression data on oral squamous cell carcinoma (OSCC). a A gene dendrogram is constructed by average
linkage hierarchical clustering. The color row underneath the cluster tree shows module assignment implemented by the dynamic tree cut
method.b The Z-summary statistic (y-axis) of the original data modules against 100 random samples is plotted as a function of module size. Each
circle represents a module labeled by a color and module name. The dashed redline denotes a significance threshold (Z = 10)
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100 random samples from the merged dataset, we found
that module preservation (mean Z-summary scores) ranged
from 6.86 to 30.27 (Fig. 3b). Except for “tan”, which was
moderately preserved, all modules were found to be above
the significance threshold of 10. Module preservation was
also fairly consistent across the majority of the boot-
strapped networks obtained from an individual contribut-
ing dataset (Additional file 3: Table S1). We concluded that
the majority of candidate modules can be considered mod-
erately to highly reproducible. These results indicated that
the modules identified were not dataset specific, but robust
and highly reproducible structures.
Analysis of modules associated with cancer stage
In comparison with the analysis of correlations of individ-
ual genes with clinical traits, module eigengenes (MEs)
offer a major advantage because they reduce multiple test-
ing from thousands of transcripts to the number of mod-
ules. By analyzing correlations of MEs with a stage
phenotype, we obtained the most significant associations
and identified groups of genes with strong relationships
with an OSCC stage (Fig. 4a). For each correlation,
p-values were computed and multiple testing corrections
were performed using the Benjamini & Hochberg method
for calculation of the FDR adjusted p-value (q-value).
Among the 13 resulting modules, MEs that signifi-
cantly correlated with phenotypic data of cancer stage
were labeled “candidate modules” at the defined cut-
offs (absolute correlation [r] ≥0.3 and r ≤ −0.3). ME of
the pink module was found to positively correlate (r = 0.33,
p = 5.5 × 10−04) with the stage; this module contains mostly
those genes that were overexpressed at the cancer stage in
Fig. 4 Analysis of expression data on oral squamous cell carcinoma (OSCC) in the WGCNA software. WGCNA: Weighted Gene Correlation
Network Analysis. Suitability of the pink module is clearly visible.a A heatmap of module eigengenes (MEs) and correlations, where each row
represents a module (labeled by color), and each column represents a trait. The value at the top of each square represents Pearson’s correlation
coefficient between the MEs and trait, along with the associated p-value in parentheses. The red and blue colors represent a strong positive and
negative correlation, respectively, between a ME and a trait. b Module significance (MS) of all modules, with pink at the top of the plot,
indicating that expression profiles of the pink module are strongly associated with the trait. c Analysis of topological robustness of the pink
module via plotting of a simultaneous node deletion against changes in the size of the largest component, σ(ρ), when the fraction ρ of the
vertices (nodes) was removed. The results indicate network robustness. d The plot of gene significance (GSiGS) against scaled connectivity (Ki)
where each point (“darkgolden” and “darkcyan”) corresponds to a gene in the pink module. Intramodular connectivity significantly correlated with
gene significance (r = 0.36, p = 8.3 × 10−5). All large labeled nodes (GSi >0.2 and Ki > 0.3) are the identified hubs. Among these, darkgolden nodes
represent hubs with the strongest correlation with the phenotype (GSi >0.2, Ki > 0.3, and f >675); these hubs represent “key hub genes”
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question. In contrast, MEs of the black module (r = −0.33,
p = 5.5 × 10−04) and turquoise module (r = −0.35, p = 5.5 ×
10−04) correlated with the stage negatively; therefore, this
result indicated that the genes in these modules had low
transcript levels at the cancer stage in question. Expression
patterns for each significant module were also unique
(Additional file 2: Figure S8). In an attempt to find
correlations of significant modules with gene expres-
sion profiles, we also defined GSi and module signifi-
cance (MS) network metrics. GSi is the absolute value
of correlation between a gene and a phenotype, and
MS is average absolute GSiGS for all genes in a par-
ticular module. Figure 4b shows that pink, black, and
turquoise modules stood out (had the highest MS), with
pink at the top. Possible marker genes are specifically up-
regulated in the majority of tumors [61–63] and hence
can be used to classify cancers according to stage [64].
The pink module (114 genes) was therefore finally se-
lected on the basis of the strongest positive correlation
with a stage and slightly higher module significance in
Fig. 5 Visualization of hub genes in the pink module network. All gene-to-gene correlations were selected in the pink module, and the network
was visualized by means of the Cytoscape software. Edge (grey) width is proportional to the weight of the correlation between two genes. All
large labeled nodes are the identified hubs (gene significance [GSiGS] >0.2 and scaled connectivity [Ki] > 0.3), whereas darkgolden nodes represent
hubs that show the strongest correlations with the phenotype (these are “key hub genes”)
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comparison with the black and turquoise modules. The
strong correlations suggested that the genes in the pink
module contribute to or are driven by cancer stage.
Visual representation of the pink module network is
provided in Fig. 5.
Topological robustness of the stage-associated module
Scale-free networks are prone to fragmentation under
targeted attacks, and a decrease in network size, relative
to the original size, represents inability of many partners
to interact. Thus many biological processes are affected.
It is apparent from the figure (Fig. 4c) that the pink
module network almost precisely followed similar trends
of vulnerable to a simultaneous targeted attack accord-
ing to all centrality measures, thus reflecting their al-
most equal topological contribution to network integrity.
Nevertheless, random (i.e., non-targeted) attack was
much less effective at degrading the network structure.
Similar effects of removal of hub nodes and removal of
nodes with large BC values can be attributed to the fact
that BC nodes are correlated with hub nodes [65], and
are centrally located from the network point of view. A
similar conclusion may also be drawn about other cen-
trality measures; this situation is indicative of their ad-
vantageous locations in the network allowing them to
act as intermediaries. The size of the largest connected
component reduced gradually and reached zero after re-
moval of ~40 % of nodes. Existence of a connected com-
ponent until such a large percentage of nodes was
removed is indicative of network robustness. Because
central nodes were found to be responsible for network
integrity, owing to the promiscuous interactions, these
nodes may be useful for biological interpretations.
Identification of cancer hub genes
Genes with significant interaction partners, also called
hubs, are frequently found among existing cancer thera-
peutic targets and offer a promising approach to identify
key genes. In this study, we assumed intramodular con-
nectivity because it is far more meaningful than whole-
network connectivity. Highly connected hub nodes are
central to the network architecture [66] but may not al-
ways be biologically significant [67]. In practice, a combin-
ation of Ki and GSi prioritizes genes that not only are
central in network but also have phenotypic significance.
A significant positive correlation (r = 0.36, p = 8.3 × 10−05)
for such a small number of genes indicated that genes
with higher connectivity tend to have a stronger associ-
ation with cancer stage. Cancer genes often function as
network hubs that are involved in many cellular processes
[68], and play a pivotal role in the underlying mechanisms
of disease. A total of 63 hub genes were obtained as rea-
sonably good representatives of the pink module at the
raised cutoff, and this number constituted ~55 % of all
genes in the module (Fig. 4d). If eigengenes can explain a
relatively large part of total variance of gene expression
levels, then the subset of genes is considered important.
Hub genes accounted for ~43 % of variation in the pink
module eigengene; this result is relatively good, given that
OSCC is a complex trait.
To find relations of known associations between the
identified hubs and cancers, we obtained a list of gen-
es—for which mutations have been causally implicated
in cancer—from the Catalogue of Somatic Mutations in
Cancer (COSMIC) database [69]. A list of tumor sup-
pressor genes was also retrieved from the Tumor
Suppressor Genes Database (TSGene) [70]. Not sur-
prisingly, hubs included many genes that were already
known to be involved in cancers. Of the 63 hubs,
seven are annotated as well-known tumor suppressor
genes, including MET, DUSP6, DKK1, TES, ITGB1,
PTPRK, and TNFRSF10B. It is worth noting that som-
atic mutations in seven hub genes—EGFR, MET, MYO5A,
PLAG1, PTPRK, SDC4, and HMGA2—have been impli-
cated in cancer. Additionally, by means of data from other
studies, various hub genes were found to be directly impli-
cated in either OSCC or HNSCC, including known roles
in other cancers (Additional file 3: Table S2).
Analysis of the hub genes for functional pathway
enrichment
Hub genes are thought to be candidate drivers of a mod-
ule; therefore, elucidation of their associated pathways
should provide insights into the altered biological mech-
anisms in a diseased condition. Many of the existing
pathway analysis methods are focused on either the
number of DEGs in a pathway or on the correlation
among genes in the pathway [71], thus disregarding the
information about complex gene interactions. SPIA
takes into account the information from a set of DEGs
and their fold changes as well as a pathway topology in
order to assess the significance of pathways and to ob-
tain a global probability value (PG). PG is obtained by
combining PNDE and PPERT by Fisher’s method where
PPERT and PNDE are the over-representation of DEGs in a
given pathway, and abnormal perturbation of that path-
way, respectively. Pathways significant at the 1 % thresh-
old after the Bonferroni- and FDR-corrections of PG are
shown as red and blue data points, respectively, in Fig. 6.
SPIA revealed five significantly perturbed (p <0.01) path-
ways, including two activated (“small cell lung cancer”
and “pathways in cancer”) and three inhibited pathways
(“direct p53 effectors”, “mcalpain and friends in cell mo-
tility”, and “a6b1 and a6b4 integrin signaling”;
Additional file 3: Table S3). Overall, these pathways me-
diate cellular processing, signal transduction and cancer
mediated processes. Activation of the “pathways in
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cancer” and “small cell lung cancer” pathways can be dir-
ectly attributed to OSCC progression.
The p53 protein regulates the cell cycle and functions
as a tumor suppressor [72], and inhibition of p53’s regu-
latory elements leads to dysregulation of various tumor-
suppressing processes, including DNA repair, cell cycle
arrest, senescence, and apoptosis. Moreover, p53 is also
the most frequently mutated gene in oral cancer [73].
Calpains have been shown to play a pivotal role in can-
cer development and progression, cell transformation,
tumor invasion, apoptosis, angiogenesis [74], and cell
migration [75],which is a critical step in tumor invasion
and metastasis. The m-calpain is also required for
growth factor receptor-mediated de-adhesion and motil-
ity [76]. Activity and protein expression of m-calpain are
significantly elevated in cancers [77], but paradoxically
this pathway was found to be inhibited.
Numerous studies have shown altered integrin ex-
pression profiles during cancer growth and progres-
sion, and this kind of changes contribute to the
aggressive behavior of cancer cells [78]. Moreover, the
involvement of α6β4 integrin in cancer progression
has been well elucidated [79], but few reports de-
scribed the role of α6β1 integrin in tumor progression
[80]. Furthermore, it is known that dysfunctional in-
tegrin signaling is involved in the detachment of
tumor cells from neighboring cells, ensuring enhanced
survival and proliferative abilities [81]. Altogether, our
results indicated that the pink module may also be
considered as an oncogenic one because it is enriched
in well-known cancer-related pathways.
Analysis of the hub genes for gene ontology enrichment
To obtain functional annotation of gene products, GO
BP defines biological events to which a gene or gene
product contributes [46]; therefore, enriched GO BP
terms tend to provide insights into functional character-
istics of genes. For hubs to be of significant relevance,
they would have to carry ontological signatures specific
to cancer. We found that major significantly enriched
so-called supercluster terms were related to molecular
mechanisms associated with a “polyphosphate metabolic
process” (GO:0006797), “cellular response to vitamin
D” (GO:0071305), “mitotic G2 phase” (GO:0000085),
Fig. 6 Significantly enriched pathways among the hub genes. A two-way evidence plot of signaling-pathway impact analysis (SPIA) for each
pathway is represented by one dot. Pathways on the right of the red oblique line (red dots) are statistically significant at the 1 % threshold after
Bonferroni correction of global p-values (PG) obtained by combining (by Fisher’s method) over-representation of differentially expressed genes
(DEGs) in a given pathway (PPERT) and an abnormal perturbation of the pathway (PNDE). The pathways on the right of the blue oblique line (blue
dots) are statistically significant after false discovery rate (FDR) correction of PG
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“regulation of single stranded viral RNA replication via
double stranded DNA intermediate” (GO:0045091),
“negative regulation of keratinocyte proliferation”
(GO:0010839), and “gland morphogenesis” (GO:0022612;
Table 2). Enrichment in the polyphosphate metabolic
process may be directly related to the enhanced metabolic
activity and energy consumption rate. Polyphosphate
(polyP) performs an important role in apoptosis and en-
hancement of mitogenic activity of fibroblast growth fac-
tor [82], but polyP’s precise role is poorly understood.
Phosphate can act as a signaling molecule on the extracel-
lular signal-regulated kinase (ERK1/2) [83] and adenylate
cyclase/cAMP signaling pathways [84], and can ultimately
affect cell growth. PolyP levels are also found to be in-
creased in glioma and lung cancer cells [85].
Some processes were also found to be altered in relation
to vitamin D stimulus (cellular response to vitamin D).
Vitamin D receptor (VDR)—a key mediator of the vitamin
D pathway—has been implicated in insulin-like growth
factor signaling, inflammation, estrogen-related pathways,
and activation and regulation of vitamin D and calcium.
Involvement of VDR in multiple pathways and points of
convergence within these pathways indicate its possible
importance for etiology of cancers [86]. Furthermore,
polymorphisms in the VDR gene are associated with pros-
tate cancers; this finding supports the role of VDR in the
risk of some type of cancers [87, 88]. Therefore, in theory,
there may be dysregulation of processes or genes involved
in the pathways associated with VDR.
Because cancer cells continue to reproduce indefin-
itely, as expected, biological activities are also signifi-
cantly altered in cell cycle regulation. The enriched term
mitotic G2 phase [89] is known to be directly linked to
tumorigenesis and progression of cancer [90], contribut-
ing to a faster cell cycle during tumor growth. Some
types of oral cancers are linked to human papilloma
virus (HPV). Although epidemiology of oral HPV infec-
tion is not fully understood and its prevalence and im-
portance are controversial, the enriched term regulation
of single stranded viral RNA replication via double
stranded DNA intermediate [91] may point to the al-
tered processes due to HPV infection [92]. The GO term
negative regulation of keratinocyte proliferation related to
processes associated with multiplication or reproduction
of keratinocytes; these processes ultimately increase the
cell population. Malignant oral keratinocytes express 5–50
times more EGFR than do their healthy counterparts [93];
therefore, activation of EGFR enhances proliferation and
the metastatic potential of keratinocytes [94].
The enriched term gland morphogenesis possibly indi-
cates alteration of some processes during salivary gland
neoplasia [95] as it is an outcome of modified morpho-
genetic events. Other noteworthy BP terms, including
their child terms, are provided in Additional file 3 (Table
S4). Non redundant BP terms were subsequently visual-
ized as a tree map (Additional file 2: Figure S9). Since
GO terms revealed significant enrichment in processes
implicated in cancer progression, this finding provided
evidence that hub gene-mediated processes were signifi-
cantly dysregulated during OSCC progression.
Regularized logistic regression modelling
Among the hub genes selected, some may be irrelevant to
the trait of interest; therefore, we performed multivariate
logistic regression modeling to reduce the dimensionality
of the feature space and to identify the best subset of hub
genes (those that have the strongest correlations with the
phenotype in question). The elastic net, an automatic
method of variable selection, interpolates between L1-
(LASSO) and L2- (ridge) regularization and can effectively
Table 2 Categories of functionally enriched gene ontology (GO) biological processes (BPs) in the pink module. The latter is the
cancer-associated module, and hub genes from this module are shown in the table




Genes in GO category
polyphosphate metabolic process GO:0006797 0.001 5.789 × 10−03 MINPP1
cellular response to vitamin D GO:0071305 0.040 2.153 × 10−05 AHR, APP, ATP2C1, CXCL5, CYP27B1, DFNA5, DKK1, DUSP6, EGFR,
FGD6, GLS, GNB5, HMGA2, HOXA1, IL8, IRS1, ITGB1, MET, MTMR2,
MYO5A, PANX1, PSPH, PTHLH, PTPRK, RAB8B, SLC12A2, SLC20A1,
SNAI2, STC1, STK3, TNFRSF10B
mitotic G2 phase GO:0000085 0.013 1.156 × 10−03 APP, E2F3
regulation of single stranded viral RNA
replication via double stranded
DNA intermediate
GO:0045091 0.009 4.873 × 10−04 AHR, APP, ATP2C1, CYP27B1, DFNA5, DKK1, DUSP6, E2F3, EGFR, FGD6,
HMGA2, HOXA1, IL8, IRS1, ITGB1, LPCAT1, MET, MTMR2, PANX1, PLAG1,
PTHLH, RAB8B, RSF1, SDC4, SLC20A1, SNAI2, STC1, STK3, TNFRSF10B
negative regulation of keratinocyte
proliferation
GO:0010839 0.015 4.873 × 10−04 APP, CXCL5, E2F3, EGFR, HMGA2, IRS1, ITGB1, MMP12, PLAG1, PTHLH,
PTPRK, SNAI2
gland morphogenesis GO:0022612 0.399 2.716 × 10−05 AHR, APP, ATP2C1, CHSY1, COL4A5, CYP27B1, DFNA5, DKK1, DUSP6,
EGFR, FGD6, GNA12, HMGA2, HOXA1, IL8, IRS1, ITGB1, LAMA3, LAMC2,
LPCAT1, MET, MINPP1, MMP10, MMP12, MTMR2, MYO5A, PLAG1,
PTHLH, SEMA3C, SLC12A2, SNAI2, SNX10, STC1
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shrink coefficients and set some coefficients to zero. After
running 1000 bootstraps, we obtained a frequency (f )
ranked gene list based on how often a gene was included
in each bootstrap. The optimal subset of features
consisted of genes that were present at a greater-than-
selected threshold (GSi >0.2; Ki >0.3; f > 675) and therefore
were considered to be “key hub genes” in this study. Fi-
nally, 13 key hub genes—CBX3, PSPH, ATP2C1, SNX10,
MMD, ATP13A3, GLS, EGFR, GNA12, ABCC4, HMGB3,
HMGA2, and HOXA1 (Table 3)—were consistently identi-
fied as important above the selected thresholds. It is
noteworthy that many of the selected genes have well
known cancer associations (see Discussion). Visual
representation of key hub genes in the pink module
network is provided in Fig. 5.
After performing feature selection, a classifier model was
also built using the above-mentioned 13 genes to determine
whether the identified candidate genes can discriminate be-
tween early- and late-stage OSCC samples. The classifica-
tion accuracy (AUC) of the five generated models was
found to be 0.88, 0.73, 0.85, 0.84 and 0.72, with the average
of ~0.81 (Fig. 7). Since the average AUC value was
greater than 0.50, the classification algorithm screening
performed better than did random discrimination. Fur-
thermore, the resulting prediction model was also eval-
uated on an independent dataset containing 54 late-
and 41 early-stage OSCC tumor samples. The gene ex-
pression dataset (GSE41613) obtained was measured by
means of an Affymetrix array containing expression
and phenotypic data from HPV-negative OSCC samples
(of a known stage) [96]. Using our model, we obtained
a reasonable ~61 % accuracy in the independent data-
set. Overall, these results indicated that gene features
that we identified offered substantial predictive power
for classification by phenotype-associated stages (early-
versus late stage).
Discussion
The clinical stage of cancer is the most important deter-
mininant of a treatment regimen for a patient and is use-
ful for assessment of the risk of metastases and for
prediction of recurrence and mortality in patients with
oral cancer; thus, the cancer stage is an efficient tool for
improvement of survival rates. Accordingly, to improve
the survival rates among the patients, OSCC should be
diagnosed as early as possible. Given the difficulty of pro-
curing stages in cancer, it is important to determine ex-
pression profiles of genes associated with these stages.
The emerging field of systems biology can help to eluci-
date biological mechanisms underlying complex traits and
may provide a functional context for identifying those
genes that contribute to cancer development. Alterations
in gene expression correlate with a tumor histotype, grade,
and stage. Various researchers have utilized differential ex-
pression analysis along with coexpression network mining
and identified important regulatory networks in cancer
datasets [97]. Furthermore, network-based approaches
are known to perform better at prediction of cancer
metastasis in comparison with gene-based approaches
[98]. Considering these advantages, we implemented a
meta-analysis and knowledge-independent approach to
construct a gene coexpression network and then developed
a stage prediction model to discriminate early- and late-
stage OSCC tumors. Our assumption was that a group of
interconnected genes with topological and trait relevance
Table 3 Key hub gene signatures based on an ensemble of centrality and trait relevance criteria (Gene significance [GSiGS] >0.2,











11335 CBX3 chromobox homolog 3 0.82 0.43 982
5723 PSPH phosphoserine phosphatase 0.37 0.32 980
27032 ATP2C1 ATPase, Ca++ transporting, type 2C, member 1 0.91 0.40 948
29887 SNX10 sorting nexin 10 0.72 0.38 936
23531 MMD monocyte to macrophage differentiation-associated 0.57 0.37 936
79572 ATP13A3 ATPase type 13A3 0.74 0.38 929
2744 GLS glutaminase 0.70 0.37 923
1956 EGFR epidermal growth factor receptor 0.63 0.33 869
2768 GNA12 guanine nucleotide binding protein (G protein) alpha 12 0.80 0.37 840
10257 ABCC4 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 0.46 0.32 770
3149 HMGB3 high mobility group box 3 0.74 0.36 765
8091 HMGA2 high mobility group AT-hook 2 0.81 0.34 744
3198 HOXA1 homeobox A1 0.75 0.34 676
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(rather than a large number of individual genes) may yield
most reliable predictions regarding an OSCC stage.
Thus, the WGCNA-based gene coexpression network
was analyzed here to identify modules of strongly corre-
lated genes during OSCC stage progression. Although
many alternative coexpression network methods have
been proposed [99], WGCNA offers several valuable
opportunities including interpretation of module robust-
ness, calculation of network properties, and the possibil-
ity of association of modules with external clinical traits.
In this study, the network was based on analysis of
tumor samples; therefore, it can provide a glimpse into
the disease status where specific characteristics of stage
progression are involved. Because modules showed
genes of biological interest, focusing on them seems to
be a biologically meaningful data reduction scheme. One
coexpression module (pink) was found to be strongly as-
sociated with cancer stages (Fig. 4a), suggesting that
genes in this module contribute to or are driven by a
cancer stage. Furthermore, the pink module is also dis-
tinct from the others in the sense that genes within this
module positively correlate with the phenotype of an
OSCC stage and offer the highest significance of the
module as well (Fig. 4b).
Gene regulation occurs in the context of complex net-
works of interactions among multiple genes rather than
in a linear one-to-one process [100]. Much attention has
been focused on the modular approach to selection of
targets for a therapeutic intervention. In the present
study, we further refined the core of oncogenic module
by identifying the most central genes also called hubs. It
is worth noting that the number of hubs depends upon
the threshold and can be varied accordingly. Modules
may arise due to non-biological variation; therefore they
were tested for enrichment.
As mentioned earlier, different cancers can share com-
mon characteristics including cell cycle regulation [90],
phosphate metabolic processes [84], and regulation of
keratinocyte proliferation [93] (Table 2).Our findings are
consistent with the notion that these common processes
are associated with cancers.
Additionally, ontological associations of hub genes can
be extended to a neighboring highly connected gene clus-
ter comprising coexpressed genes, within the confines of a
given module. Besides categories related to cancer-
associated ontological terms, these central players showed
direct significant evidence of known cancer-associated
pathways. Several of the hub genes that we identified in
Fig. 7 The plot of a receiver-operating characteristic (ROC) curve. The average area under the curve (AUC) of ~0.81 denotes the accuracy of the
signature of key hub genes in the test dataset. The ROC curve depicts a true positive rate (sensitivity) versus a false positive rate (one minus specificity).
The diagonal line in the ROC plot has an AUC value of 0.5, representing the predictive power of a random guess. The graph was rendered in the
ROCR software
Randhawa and Acharya BMC Medical Genomics  (2015) 8:39 Page 14 of 20
the pink module are consistent with the results of other
studies on cancer, though some hub genes did not show
any association with OSCC. Apart from their topological
centrality, gene significance—which measures the strength
of differential gene expression between the early- and late-
stage groups—also points to an important association of
these genes with the phenotypic traits of an OSCC.
A smaller number of biomarkers often does not per-
form well, whereas a cancer classification system that is
based on an expression profile of a reasonable number
of genes can outperform standard systems that are based
on clinical and histological criteria [101, 102]. Feature
screening is a useful approach to analysis of multidimen-
sional data with the aim of identifying all features rele-
vant to the response variables. Elastic-net regression has
been proposed as a way to select significant features and
was even used to select genes relevant to diagnosis or
prognosis of a disease [103, 104]. In our analysis, elastic-
net regression modeling was used to identify the best
subset of hub genes (those that have the strongest corre-
lations with the stage phenotype). The classifier model
that was developed by means of differential expression
of 13 key hub genes was potent enough to discriminate
between OSCC stages.
Detailed and systematic literature search suggests that
dysregulation of these hub genes is directly involved in
OSCC and may play an important role in the development
of other cancers. For example, GNA12 [105], GLS [106],
SNX10 [107], and HOXA1 [108] are often dysregulated in
OSCC, while the genes CBX3 [109] and ABCC4 [110] are
differentially regulated in HNSCC. In addition, CBX3 and
ABCC4 are promising therapeutic targets in osteosarcoma
[111] and pancreatic cancer [112], respectively. CBX3 has
been reported to function in chromatin packaging and
gene expression regulation and has also been found to
possibly regulate euchromatin repression by associating
with nucleosomes in heterochromatin [113]. Some studies
have also shown that high expression of CBX3 is associ-
ated with other tumors [113].
Up-regulated genes EGFR [114] and HMGA2 [115]
are possible tumor markers of OSCC. HMGA2 was
found to be highly expressed in metastatic lung adeno-
carcinoma and contributes to cancer progression and
metastasis [116]. EGFR regulates signaling pathways
that participate in developmental processes, including
cell cycle activation, cell survival, proliferation, and
angiogenesis [117]. Furthermore, dysregulation of EGFR
is among the most frequently studied molecular events
that leads to oral carcinogenesis, and OSCCs show up-
regulation of EGFR by 42 % to 58 % [118]. Various
studies have highlighted the role of EGFR in the patho-
genesis of oral carcinoma [119], and this protein is also
frequently expressed in many types of cancer, including
HNSCC [120].
In the present study, involvement of some of the selected
genes in OSCC is not supported by direct evidence; how-
ever, they may be linked to tumorigenesis indirectly. For
example, GLS plays an important role in cell growth and
energy metabolism during cancer stage progression [121],
while HMGB3 promotes cell proliferation and migration
and is associated with poor prognosis in urinary bladder
cancer [122]. In addition to large consumption of energy,
cancer cells accumulate building blocks like nucleic acids,
lipids, and cofactors for construction of new cellular com-
ponents, including amino acids [123]. Glutamine is among
the main sources for maintenance of activity of essential
metabolic pathways such as glycolysis and the anaplerotic
flux of the tricarboxylic acid cycle. GLS converts glutamine
to glutamate and performs an important function in cell
growth and energy metabolism during cancer stage pro-
gression [121]. Furthermore, some reports have suggested
that inhibition of GLS slows down the growth of glioblast-
oma cells and therefore may be therapeutic strategy against
such cancers [121].
Although precise role of the HMGB3 gene has not
been determined in OSCC, this gene promotes cell
proliferation and migration and performs an import-
ant function in DNA replication, recombination, and
repair [122]. Altered expression of this gene is also as-
sociated with other cancers including urinary bladder
cancer [122], metastatic breast cancer [124], and gas-
tric cancer [125].
Metabolic processes can be adapted in a way to drive
macromolecular biosynthesis for rapid cell growth and
proliferation [126]. Serine can be converted to glycine,
which provides carbon units for one-carbon metabolism;
therefore, the serine biosynthetic pathway plays a crucial
role in glucose conversion [127]. The PSPH gene was
found to be upregulated in the L-serine biosynthetic
pathway during metastasis [128]. Serine biosynthesis is
also elevated in tumor lysates [129], where PSPH acts as
a rate-limiting enzyme of this pathway [130]; this finding
is indicative of its regulatory role in tumor progression.
Tumor-associated macrophages (TAMs) have both
positive and negative effects on tumor growth of various
cancers. Since TAM expression is significantly associated
with stages of invasion, these cells possibly play a role in
angiogenesis during oral cancer progression [131].
MMD, a gene associated with differentiation of mono-
cytes into macrophages, is a key signature of a relapse
and survival among patients and is involved in lung can-
cer [132]. Although function of the MMD protein is un-
known, certain studies have shown that macrophage
activation promotes cancer metastasis [133].
GNA12 mRNA levels are significantly upregulated in
OSCC, and consistently high levels of the GNA12 protein
expression are detected in ~75 % of OSCC tissues. Over-
expression of this protein drives migration and invasion of
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oral cancer cells; targeting of GNA12 was proposed for
prevention of metastasis [105].
Although the expression profile and function of
ABCC4 in OSCC remain unclear, this gene is a promis-
ing target for treatment of pancreatic cancer[112].
HOXA1 is dysregulated in various cancers, for example
it is overexpressed in OSCC [108] (where it promotes
cell proliferation) and is downregulated in small cell lung
cancer [134].
MicroRNAs are important for regulation of post-
transcriptional repression of some genes and have been
identified as statistically unique markers for discrimination
of cancer from healthy tissue, thus serving as a valuable tool
for cancer diagnosis [10, 135]. Differentially expressed
microRNAs have been found to tightly regulate four of the
possible biomarkers that we identified—HMGA2, EGFR,
HOXA1, and ABCC5/ABCC4 [10]—further supporting
their involvement in oral-cancer progression. Although the
exact role of some of the selected genes—PSPH, ATP2C1,
MMD, ATP13A3, ABCC4, and HMGB3—has not been
established in OSCC, a modular hierarchy and “guilt-by-as-
sociation” rule may be utilized to identify the direct (or in-
direct) association of these genes with OSCC. Because
these hub genes have good predictive power at distinguish-
ing OSCC stages, they may provide new insights into the
biological mechanisms underlying the stage progression.
Our study was somewhat limited by the next-generation
sequencing data perspective [136], and we used a relatively
small set of genes in the coexpression analysis. Addition-
ally, due to limited availability of clinical data, it was not
possible to incorporate other phenotypic parameters into
our analysis (e.g., cancer grade and type). Nevertheless, our
study has several strengths including the use of multiple
large datasets, careful QC, a powerful statistical approach
to identification of modules, and a well established and val-
idated model that can effectively discriminate between
early- and late-stage OSCC tumors. Despite simplicity, our
systematic analysis illustrates a method for classification of
OSCC stages; this method can help researchers to identify
the cancer stage by means of molecular features instead of
histopathological analysis or measurement of tumor size.
With the availability of additional samples and inclusion of
more clinical and topological feature vectors, the accuracy
of this prediction model may be enhanced. We expect that,
if confirmed in empirical studies, the selected gene features
will speed up the discovery of molecular signatures of stage
progression in OSCC. This approach may also open up op-
portunities for development of novel diagnostic modalities
or therapeutic interventions in other cancers.
Conclusions
We present a systematic computational and statistical
pipeline, comprising differential expression, analysis of
a gene coexpression network, and logistic regression
modeling. This method helped us to identify13 key hub
genes as features associated to stage progression in
OSCC. We were able to differentiate between early-
and late-stage tumor samples on the basis of differences
in expression profiles of the 13 identified genes. Al-
though some of the hub genes are OSCC-specific, many
have been implicated in other carcinomas. Since all
genes in a module are strongly associated, our results
may point to a number of other promising candidate
genes that warrant further analysis; hence, empirical
studies will be needed to address their specific roles.
For example, the precise roles of some of our selected
genes—PSPH, ATP2C1, MMD, ATP13A3, ABCC4, and
HMGB3—are unknown in OSCC. If characterized, these
genes may define OSCC-associated processes or may
serve as possible therapeutic targets. The selected gene set
may turn out to be a valuable reference set for identifica-
tion and validation of biomarkers of OSCC. To the best of
our knowledge, this study is the first implementation of
key hub genes (by means of expression profiles and coex-
pression network) to develop a classification model for
OSCC stages.
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Additional file 1: (Supplementary Methods).
Additional file 2: Figure S1. (Supplementary Figures). Expression
intensity distributions of arrays. Density plots of arrays of probe-level data
before (A) and after (B) normalization. Figure S2.Expression intensity
distributions of arrays. Box plots of arrays of probe-level data before (A)
and after (B) normalization.Figure S3. Heatmap plot analysis of merged
gene expression data without (A) and with (B) batch effect removal
approach. The hierarchical clustering was performed by means of gplots
software package. Ward's method with Euclidean distance metric was
used for the clustering. The samples are displayed on the X-axis while
genes are listed on the Y-axis. The vertical branches of cluster,
representing samples, are color coded according to group with “dark-red”
and “forest-green” for cancer and normal samples, respectively. The
resulting heatmap shows that the samples are clustered together by data
source when they are simply merged (A); however, after the application
of COMBAT, the influence of data source on grouping is significantly
reduced (B). This COMBAT-merged method resulted in clustering of the
samples into their distinct normal and cancer groups. Figure S4. Relative
log expression (RLE) boxplots. A plot indicating mean of RLE is not
centred around zero and represent an uneven spread when they are
simply merged (A); however, after the application of COMBAT, the mean
of RLE plot was distributed around zero for all genes (B). This result is an
indicative of removal of batch effect by COMBAT-merged method.
Additionally, the plot highlighted the existence of 7 clear batches in
simply combined datasets (A); however, COMBAT-implementation
method greatly improved the appearance of plot (B). All samples are
color coded based on biological variable of interest (healthy (red); cancer
(green)). Figure S5. Volcano plot of differentially expressed genes (DEGs).
The log2 fold change is plotted on the X-axis and the negative log10
adjusted p-value is plotted on the Y-axis. Cyan circles graphically display
1652 genes that satisfy both criteria of p-value (False Discovery Rate
[FDR] < 0.05) and fold change (>two-fold change). Figure S6. Clustering
analysis of differentially expressed genes (DEGs). The hierarchical
clustering was in the gplots software package. Ward's method with
Euclidean distance metric was used for the clustering. The clustering of
DEGs shows a distinct separation between normal and cancer groups.
The samples are displayed on the Y-axis and genes are listed on X-axis.
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The vertical branches of cluster, representing samples, are color coded
according to group with “dark-red” and “forest-green” for cancer and
normal samples, respectively. Figure S7. The node degree distribution of
Oral Squamous Cell Carcinoma disease network. The number of nodes
(i.e., genes) is plotted as a function of their degree which reflects a
power-law like distribution; this is an indicative of scale-free network
topology. The red line corresponds to a power-law distribution with
parameters xmin = 44 and α = 6.62, where xmin is lower cut-off and α is
the scaling parameter. Figure S8. The expression heatmap plots of
modules correlated with a stage. The rows correspond to genes and the
columns to random samples. Here, in this figure, genes color coded
green are underexpressed, while red indicates overexpression. Figure S9.
The enriched gene ontology (GO) terms obtained for hub genes. The
enrichment analysis (Fisher exact test p < 0.05) is carried out by means of
GoStats software package and summarized using REVIGO.
Additional file 3: Table S1. (Supplementary Tables). The Z-summary
statistics of modules obtained against bootstrapped networks from the
individual dataset from Gene Expression Omnibus (GEO). Table S2. The
roles of hub genes (corresponding to pink module) highlighting their
significance in OSCC and other cancers. Table S3. The perturbed
pathways obtained in hub genes on the basis of combined Signaling
Pathway Impact Analysis (SPIA) criteria after a False Discovery Rate
correction of 1 % on the global p-values (pG). (pSize: number of genes in
the pathway; NDE: number of DE genes in the pathway; pNDE:
Probability to observe at least NDE genes in the pathway using a
hypergeometric model; tA: observed total perturbation accumulation in
the pathway; pPERT: probability to observe a total accumulation more
extreme than tA by chance; pG: p-value obtained by combining pNDE
and pPERT; pGFdr: False Discovery Rate; Status: Direction in which the
pathway is perturbed). Table S4. The REVIGO summarized biological
process (BP) categories terms for hub genes (corresponding to pink
module).
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